| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
- Balance sheet strengthened with long-term, non-dilutive capital
- $400 million funded at close with the potential to draw an additional $100 million
- Immediately enhances Arrowhead's ability to advance plozasiran towards a 2025 launch
- Expands possibilities to fund innovation and growth across Arrowhead's robust and diverse pipeline of RNAi therapeutics
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has entered into a strategic financing agreement with Sixth Street for significant, long-term, non-dilutive capital to fund innovation and growth opportunities across Arrowhead's robust and diverse pipeline of RNAi therapeutics. The $500 million senior secured credit facility includes $400 million funded at close with an additional $100 million available at Arrowhead's option, subject to mutual agreement between Sixth Street and Arrowhead, during the seven-year term of the agreement.
Posted In: ARWR
